Examining Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Efficacy in Managing LDL-C Levels and Reducing Cardiovascular Events

This review of literature critically examines the role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors in conjunction with current treatments to reduce cardiovascular events and mortality among patients with Atherosclerotic Cardiovascular Disease (ASCVD). Emphasizing the prevalent issue of ASCVD as a major contributor to morbidity and mortality in the United States, this review focuses on the pivotal role of low-density lipoprotein cholesterol (LDL-C) in ASCVD progression. It highlights the substantial number of patients on cholesterol lowering regimens who fail to achieve optimal LDL-C levels. The use of PCSK9 inhibitors is explored as an adjunct to current treatments or as an alternative therapeutic option, showcasing their effectiveness in lowering LDL-C levels. Additionally, the manuscript navigates the hurdles and limitations healthcare providers face in prescribing these inhibitors, offering a comprehensive review of LDL-C management in ASCVD patients and the promise of PCSK9 inhibitors.